18:32 , Nov 30, 2018 |  BC Week In Review  |  Company News

BioBlast merging with Enlivex

BioBlast Pharma Ltd. (NASDAQ:ORPN) will merge with Enlivex Therapeutics Ltd. (Jerusalem, Israel), which is developing its Allocetra cell therapy program. In 4Q19, Enlivex expects to begin a Phase II trial of the therapy to treat...
22:03 , Sep 18, 2017 |  BC Extra  |  Company News

Management tracks: Kamada, Vertex, Addex, Achillion

Orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said Deputy CEO and CFO Gil Efron will leave at the end of the year. Chaime Orlev will become CFO, effective Jan. 1, 2018. Orlev was CFO...
23:12 , Apr 13, 2017 |  BC Week In Review  |  Financial News

BioBlast Pharma withdraws follow-on

Rare disease play BioBlast Pharma Ltd. (NASDAQ:ORPN) withdrew its follow-on underwritten by H.C. Wainwright on April 6, citing market conditions. In February, the company proposed to raise up to $11.5 million. BioBlast Pharma Ltd. (NASDAQ:ORPN),...
01:16 , Mar 2, 2017 |  BC Week In Review  |  Financial News

BioBlast Pharma proposes follow-on

On Feb. 24, rare disease play BioBlast Pharma Ltd. (NASDAQ:ORPN) proposed to raise up to $11.5 million in a follow-on underwritten by H.C. Wainwright. BioBlast Pharma Ltd. (NASDAQ:ORPN), Tel Aviv, Israel ...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Company News

BioBlast Pharma musculoskeletal news

BioBlast is reducing headcount by 8 (40%) to 12 and will focus development on 90 mg/mL IV trehalose (formerly Cabaletta ). The cuts include Chief Commercial Officer Paul Firuta, Chief Corporate Development Officer Theresa Stevens...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
01:45 , May 5, 2016 |  BC Extra  |  Company News

Management tracks

Gene therapy company uniQure N.V. (NASDAQ:QURE) named Paul Firuta chief commercial officer. He was chief commercial officer at BioBlast Pharma Ltd. (NASDAQ:ORPN). Metabolic company Orexigen Therapeutics Inc. (NASDAQ:OREX) named Brian Longstreet SVP of global market...
07:00 , Mar 21, 2016 |  BC Week In Review  |  Financial News

BioBlast Pharma completes direct public offering

BioBlast Pharma Ltd. (NASDAQ:ORPN), Tel Aviv, Israel   Business: Musculoskeletal   Date completed: 2016-03-17   Type: Direct public offering   Raised: $6.7 million   Shares: 2.2 million   Price: $3.10   Shares after offering: 16.4...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Cabaletta: Interim Phase II data

Interim data from 25 patients with OPMD in the open-label, international Phase II HOPEMD trial showed that once-weekly 30 g IV Cabaletta led to stabilization or improvement in 10 of 12 patients evaluable for VFS-PAS....
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Cabaletta regulatory update

FDA granted Fast Track designation to Cabaletta from BioBlast to treat oculopharyngeal muscular dystrophy (OPMD). The compound is in the Phase II/III HOPE trial for OPMD, for which it has Orphan Drug designation. Cabaletta is...